- Design
- randomised, placebo-controlled pilot trial over 12 months
- Population
- 42 patients with Parkinson's disease randomised, 32 completing both visits
- Primary outcome
- one-year tolerability, with exploratory clinical and dopamine transporter imaging measures
- Effect
- total UPDRS change +5.4 vs +9.5 points, difference -4.1 (95% CI -7.6 to -0.5)
Forty-two patients with Parkinson's disease were randomised to oral N-acetylcysteine 1200 mg daily or placebo for twelve months alongside usual care, with UPDRS parts I to IV and dopamine transporter SPECT at baseline and one year. Thirty-two completed both visits.
Total UPDRS rose in both arms but less with treatment: a mean change of +5.4 against +9.5 points, a difference of -4.1 (95% CI -7.6 to -0.5, p = 0.028). Transporter binding declined less with treatment (difference +5.5 units, 95% CI 1.7 to 9.3, p = 0.006). A mood item also differed. Levodopa dose change did not differ after adjustment (-86 mg/day, 95% CI -235 to +64).
The authors' own framing is the right one and unusually candid. No multiplicity correction was applied and the results are labelled exploratory. Ten of 42 randomised patients did not complete, and the discontinuations were not characterised for adverse events - so an analysis of completers cannot establish safety. A 32-patient imaging endpoint is exactly the kind of result that has repeatedly failed to replicate in Parkinson's disease neuroprotection trials. N-acetylcysteine is cheap and widely available in India, which makes it more likely, not less, that patients will ask to start it. The answer is that this trial was designed to test tolerability and is not evidence of disease modification.
- Answer patient requests by explaining this was a tolerability pilot, not a disease-modification trial.
- Analyses were exploratory with no correction for multiple comparisons.
- Ten of 42 patients did not complete, and their reasons were not reported.
- Levodopa requirement did not differ between groups after adjustment.
- Dopamine transporter binding is a surrogate marker, not a clinical outcome.
Why it matters
This is a cheap over-the-counter compound, so the finding will reach patients before the caveats do.
Don't overread it
A pilot with exploratory, uncorrected endpoints in 32 completers - it does not establish that progression was slowed.
The statistics, in plain English
When several outcomes are tested without correcting for multiplicity, some will cross the significance threshold by chance alone, which is why the authors call these results exploratory rather than positive. The UPDRS difference has a confidence interval reaching -0.5, close enough to zero that the effect could be trivial. And analysing only the 32 who finished discards precisely the patients most likely to have stopped because of harm.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free